http://www.numerate.com/ The latest from Numerate, Inc. en-us Tue, 17 Mar 2009 18:10:00 PST Tue, 17 Mar 2009 18:10:00 PST http://blogs.law.harvard.edu/tech/rss http://www.numerate.com/newsCeliacSTTR.php Numerate Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today it has received a Phase 1 grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH). The Small Business Technology Transfer (STTR) award, entitled “Drug Engineering of Transglutaminase 2 Inhibitors,” will be used to support a research collaboration between Numerate and the laboratory of Chaitan Khosla, Ph.D., the Wells H. Rauser and Harold M. Petiprin Professor of Chemical Engineering and Chemistry at Stanford University. Tue, 17 Mar 2009 18:00:00 PST http://www.numerate.com/newsCeliacSTTR.php http://www.numerate.com/newsFinancing2.php Numerate, Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today that it has completed a $5.5 million Series B financing. Foundation Capital led the round and was joined by Lanza techVentures, both existing investors. Tue, 17 Mar 2009 18:00:00 PST http://www.numerate.com/newsFinancing2.php http://www.numerate.com/newsFinancing1.php Numerate, Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today that it has completed a $4 million Series A financing. Investors included Foundation Capital, Lanza techVentures and various individuals. Concurrent with the financing, Adam Grosser, a general partner with Foundation Capital, has joined Numerate’s Board of Directors. Tue, 18 Nov 2008 09:00:00 PST http://www.numerate.com/newsFinancing1.php http://www.numerate.com/newsPharmix.php Numerate, Inc., a biotechnology company with a proprietary drug design capability, announced today that it has completed the integration of Pharmix Corporation's technology platform with technologies developed at Numerate. Founded in March 2007 to rapidly deliver small molecule drug candidates with reduced risk and optimized characteristics, Numerate recently acquired all of the intellectual property of Pharmix, including all rights to Pharmix's Drug Engineering™ process and technology, as well as to four therapeutic programs. The terms of the transaction were not disclosed. Tue, 12 Feb 2008 09:00:00 PST http://www.numerate.com/newsPharmix.php http://www.numerate.com/newsPresidio.php Presidio Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing novel, small molecule compounds for the treatment of HIV-1 and HCV and Numerate, Inc., a biotechnology company with a proprietary drug engineering platform, announced today that they have entered into a research collaboration to discover and develop novel small molecule inhibitors of hepatitis C virus (HCV). Terms of the collaboration and the specific HCV target were not disclosed. Mon, 11 Feb 2008 09:00:00 PST http://www.numerate.com/newsPresidio.php